Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 9, 2013 - Issue 9
Submit an article Journal homepage
152
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety

William E BergerAllergy and Asthma Associates of Southern California, Mission Viejo, CA, USACorrespondence[email protected]
Pages 803-811 | Published online: 10 Jan 2014

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ranny van Weissenbruch, Ludger Klimek, Gabriella Gálffy, Melanie Emmeluth, Arkady Koltun, Ferdinand Kopietz, Duc Tung Nguyen, Hans Christian Kuhl, Wolfgang Pohl, Glenis K Scadding, David Price & Joaquim Mullol. (2020) MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis. Journal of Asthma and Allergy 13, pages 633-645.
Read now
Ludger Klimek, Jean Bousquet & David Price. (2016) Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Expert Opinion on Drug Safety 15:1, pages 117-129.
Read now

Articles from other publishers (3)

Zhenhua Zhong, Youfang Xun, Xinyi Shi, Bing Guan & Maohua Wang. (2021) Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis. European Archives of Oto-Rhino-Laryngology 279:5, pages 2457-2464.
Crossref
Eli O. Meltzer, Dana Wallace, Mark Dykewicz & Lucy Shneyer. (2016) Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds?. The Journal of Allergy and Clinical Immunology: In Practice 4:4, pages 682-688.e6.
Crossref
William E. Berger & Eli O. Meltzer. (2015) Intranasal Spray Medications for Maintenance Therapy of Allergic Rhinitis. American Journal of Rhinology & Allergy 29:4, pages 273-282.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.